All recent 8k's will benefit financially from any major funding , initial funding plans have failed because of miscalculated deals and "forced" Divi payments. The total outstanding shares/pps are a problem to attract investors and meet NASDAQ requirements. If any major Covid progress in the near future and before NGIO spin-off maybe we can absorb some of the selling and increase volume to reach higher levels.
(2)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links